Clinical trialNCT06719661CompletedInterventional

The Impact of Clinical Pharmacist Intervention and Dapagliflozin as Add-On Therapy in the Management of Type 2 Diabetes Mellitus.

SponsorUniversity of SulaimaniEnrollment138Type 2 Diabetes Mellitus (T2DM)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Diabetes mellitus is a progressive endocrine disease characterized by insulin deficiency with or without insulin resistance. Management of type 2 diabetes requires a comprehensive team following and monitoring the disease carefully. Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor, has been shown to be an effective medication for the treatment of T2DM, and has been demonstrated to improve glycemic control. The investigators believe that enrolling clinical pharmacist intervention as a part of a multidisciplinary approach and dapagliflozin is necessary to provide better patient care in patients that are on dual or triple oral hypoglycemic agents other than dapagliflozin. Therefore, the hypothesis of this study is that the impact and tolerability of clinical pharmacist-led intervention can be comparable to add on dapagliflozin alone on glycemic control in the management of T2DM.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mohammed A. Hama amin, BSc. Pharmacy
University of Sulaimani, College of Pharmacy
Principal Investigator
clinicaltrials.gov ↗
Rawa A. Ratha, Ph.D. Clinical Pharmacy
University of Sulaimani, College of Pharmacy
Principal Investigator
clinicaltrials.gov ↗
Taha O. Asaad, Professor
College of Medicine - University of Sulaimani
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Iraq

Endocrine and Diabetes Center
Sulaymaniyah, Kurdistan Region, Iraq
Ministry of Higher Education and Scientific Research, University of Sulaimani, College of Pharmacy
Sulaymaniyah, Kurdistan Region, Iraq

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dapagliflozin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Dec 2024
Primary completion: 5 May 2025
Completion: 1 Jun 2025
Last update posted: 5 Jun 2025
Registered enrollment: 138
Registry id: NCT06719661

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.